Cargando…

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction

The number of patients receiving sodium–glucose cotransporter 2 inhibitors (SGLT2is), especially those with heart failure, is increasing worldwide. SGLT2is control glycaemia by triggering glycosuria with simultaneous facilitation of a more ketogenic metabolic profile. Patients therefore are more pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavka, Luka, Bencak Ferko, Urska, Pitz, Natasa, Trpkovski, Zoranco, Lainscak, Mitja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318418/ https://www.ncbi.nlm.nih.gov/pubmed/34102028 http://dx.doi.org/10.1002/ehf2.13452

Ejemplares similares

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2020)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2022)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin/insulin/sodium bicarbonate: Euglycaemic diabetic ketoacidosis and lack of efficacy: case report
Publicado: (2022)

Empagliflozin: Euglycaemic diabetic ketoacidosis: 2 case reports
Publicado: (2021)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022)

Euglycaemic ketoacidosis in a non-diabetic primigravida following an appendicectomy
por: Dikowita, Dinushi Dilanka, et al.
Publicado: (2017)

Euglycaemic ketoacidosis during gestational diabetes with concomitant COVID-19 infection
por: Smati, Sarra, et al.
Publicado: (2021)

Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports
por: Pikovsky, Margaret, et al.
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis, masking of hyperglycaemia and hyperglycosuria: case report
Publicado: (2022)

Euglycaemic diabetic ketoacidosis after bariatric surgery: A Near-Miss!!!
por: Rathi, Shruti N., et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
por: Pandey, Arjun K., et al.
Publicado: (2022)

Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
por: Rafey, Mohammed Faraz, et al.
Publicado: (2019)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Fukuta, Hidekatsu, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
por: Feng, Bin, et al.
Publicado: (2023)

Euglycaemic ketoacidosis after abdominal surgery: Implications of SGLT2 inhibitors for anaesthesiologists – A case study
por: Kartha, Anandajith P., et al.
Publicado: (2023)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
por: Gammons, D. Taylor, et al.
Publicado: (2018)

Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides
por: Silva Enciso, J.
Publicado: (2020)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction
por: Arslan, Kadem, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction　― Novel Prospective Cohort Study ―
por: Sakai, Takaaki, et al.
Publicado: (2019)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhou, Hufang, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction
por: Patel, Yash R., et al.
Publicado: (2018)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review
por: Mentz, Robert J., et al.
Publicado: (2023)

Multiple drugs: Euglycaemic diabetic ketoacidosis, lack of efficacy and off-label use following exposure during pregnancy: case report
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion
por: Hernandez, Michelle, et al.
Publicado: (2022)

Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction
por: Abdelhamid, Magdy, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
por: Peters, Anne L., et al.
Publicado: (2015)

Sodium–Glucose Cotransporter 2 Inhibitors and Euglycemic Diabetic Ketoacidosis: Metabolic Acidosis With a Twist
por: Jaberi, Aala, et al.
Publicado: (2016)

Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
por: Kang, Dong Yoon, et al.
Publicado: (2022)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qcrokp6ltu952dm5q4ksropci9